Дибромпропамидин

Создатель

Dibrompropamidine,Aventis Pharma AS

Производственный процесс

2,2’-Dibromo-4,4’-dicyano-α,γ-diphenoxypropane (3.0 g) and anhydrous ethanol (3.0 ml) were dissolved in anhydrous chloroform (40 ml). The solution was saturated at 0°C with dry hydrogen chloride and set aside for 7 day. The iminoether hydrochloride which crystallised out, was filtered off and washed with light petroleum. The solid was added to 12% ammoniacal ethanol (47 c.c.) and the mixture was heated at 60°C for 6 hours. Solution was obtained after 3 hours and the amidine hydrochloride began to cryistallise. The mixture was ice-cooled, and the white crystalline solid was filtered off, washed with 2 N hydrochloric acid, and recrystallised twice from 0.5 N hydrochloric acid.
2,2'-Dibromo-4,4'-diamidino-α,γ-diphenoxypropane dihydrochloride (2.1 g) [another name: 4,4'-(Trimethylenedioxy)bis(3-bromobenzamidine)] separated as white prisme. Melting point 309°C. (decomp.).
Berg S.S., GB Patent No. 598,911; March 22, 1945; Assigned to May and Bakker Limited, a British Co., Dagenham, Essecs.

Терапевтическая функция

Antiprotozoal